Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 21 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-0.59 Insider Own0.36% Shs Outstand54.15M Perf Week7.40%
Market Cap3.04B Forward P/E16.55 EPS next Y3.39 Insider Trans-22.51% Shs Float53.96M Perf Month-7.24%
Income-31.82M PEG- EPS next Q0.78 Inst Own106.12% Short Float4.83% Perf Quarter-0.21%
Sales1.18B P/S2.57 EPS this Y10.27% Inst Trans1.43% Short Ratio3.98 Perf Half Y11.19%
Book/sh22.56 P/B2.49 EPS next Y9.91% ROA-1.34% Short Interest2.61M Perf Year11.45%
Cash/sh11.37 P/C4.94 EPS next 5Y-4.60% ROE-2.60% 52W Range42.75 - 64.47 Perf YTD8.54%
Dividend Est.- P/FCF99.90 EPS past 5Y- ROI-1.70% 52W High-12.90% Beta0.99
Dividend TTM- Quick Ratio2.71 Sales past 5Y1.30% Gross Margin68.83% 52W Low31.37% ATR (14)2.02
Dividend Ex-Date- Current Ratio3.17 EPS Y/Y TTM61.47% Oper. Margin10.37% RSI (14)49.12 Volatility3.63% 3.34%
Employees2900 Debt/Eq0.55 Sales Y/Y TTM13.03% Profit Margin-2.69% Recom1.80 Target Price71.56
Option/ShortYes / Yes LT Debt/Eq0.53 EPS Q/Q-668.11% Payout0.00% Rel Volume1.36 Prev Close55.63
Sales Surprise4.54% EPS Surprise50.11% Sales Q/Q10.51% EarningsMay 01 BMO Avg Volume655.14K Price56.16
SMA20-0.88% SMA50-2.53% SMA2006.69% Trades Volume890,285 Change0.95%
Date Action Analyst Rating Change Price Target Change
Mar-20-24Reiterated Needham Buy
Feb-20-24Upgrade Mizuho Neutral → Buy $60 → $70
Sep-06-23Initiated HSBC Securities Hold $52
Jul-19-23Initiated Robert W. Baird Neutral $56
Apr-14-23Initiated Mizuho Neutral $48
Dec-21-22Initiated Barclays Equal Weight $62
Apr-06-22Initiated Wolfe Research Outperform $95
Feb-24-22Upgrade UBS Neutral → Buy $96
Dec-03-21Initiated Goldman Buy $108
Aug-20-21Reiterated Needham Buy $104 → $117
Jun-18-24 09:00AM
Jun-08-24 10:08PM
Jun-06-24 07:45PM
May-23-24 09:00AM
11:50AM Loading…
May-02-24 11:50AM
May-01-24 08:12PM
Apr-30-24 09:00AM
Apr-26-24 12:34PM
04:03PM Loading…
Apr-25-24 04:03PM
Apr-24-24 10:01AM
Mar-21-24 09:00AM
Mar-20-24 09:00AM
Mar-05-24 09:55PM
Mar-04-24 04:44PM
Feb-22-24 09:58AM
Feb-21-24 03:15PM
Feb-13-24 01:04PM
04:34AM Loading…
Feb-09-24 04:34AM
Feb-06-24 06:15AM
Feb-05-24 08:00AM
Jan-10-24 05:00AM
Jan-08-24 08:30AM
Jan-04-24 09:00AM
Dec-12-23 08:02PM
Dec-05-23 09:39AM
Nov-27-23 06:04AM
Nov-24-23 02:19PM
Nov-22-23 07:55PM
Nov-09-23 09:00AM
Nov-02-23 02:48PM
Nov-01-23 09:36AM
Oct-25-23 09:00AM
Oct-06-23 08:30AM
Sep-25-23 06:01PM
Sep-21-23 07:00AM
Sep-20-23 09:00AM
Sep-05-23 09:46AM
Aug-30-23 04:05PM
Aug-24-23 09:00AM
Jul-26-23 05:21PM
Jul-03-23 03:11PM
Jun-21-23 08:00PM
Jun-17-23 10:20AM
Jun-14-23 09:00AM
Jun-13-23 09:00AM
May-29-23 11:53AM
May-18-23 07:17AM
May-08-23 09:51AM
May-03-23 07:25AM
Apr-26-23 08:00PM
Apr-20-23 08:29AM
Apr-18-23 08:26AM
Apr-17-23 05:07PM
Apr-14-23 04:30PM
Apr-13-23 06:14AM
Apr-06-23 06:21PM
Mar-31-23 10:36AM
Mar-22-23 09:00AM
Mar-15-23 09:55AM
Mar-09-23 04:05PM
Mar-02-23 07:36AM
Mar-01-23 09:22AM
Feb-28-23 10:05AM
Feb-23-23 05:50AM
Feb-22-23 06:33PM
Feb-08-23 05:06PM
Feb-03-23 11:20AM
Jan-27-23 12:55PM
Jan-18-23 09:00AM
Jan-10-23 09:15AM
Jan-07-23 09:16AM
Dec-15-22 08:58AM
Dec-13-22 04:05PM
LivaNova Plc is a global medical technology company, which engages in the development and delivery of therapeutic solutions for the benefit of patients, healthcare professionals, and healthcare systems. It operates through the following segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support (ACS). The Cardiopulmonary segment is involved in the design, development, manufacture, marketing and selling of cardiopulmonary products. The Neuromodulation segment is associated in the design, development, manufacture, marketing and selling of devices that deliver neuromodulation therapy for treating DRE and DTD. The ACS segment deals with the design, development, manufacture, marketing and selling of temporary life support products. The company was founded in 1987 and is headquartered in London, the United Kingdom.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
O'Kane SharonDirectorJun 15 '24Option Exercise0.002,680010,754Jun 18 04:05 PM
SCHERMERHORN TODD CDirectorJun 15 '24Option Exercise0.002,68006,643Jun 18 04:05 PM
Bianchi FrancescoDirectorJun 15 '24Option Exercise0.002,680010,857Jun 18 04:06 PM
Shvartsburg AlexCFOJun 15 '24Option Exercise0.001,576019,399Jun 18 04:06 PM
Enxing Seng StacyDirectorJun 15 '24Option Exercise0.002,68009,330Jun 18 04:06 PM
WILVER PETER MDirectorJun 15 '24Option Exercise0.002,68004,317Jun 18 04:06 PM
Story BrookeDirectorJun 15 '24Option Exercise0.002,68004,060Jun 18 04:05 PM
Moore Daniel JeffreyDirectorJun 03 '24Option Exercise57.3956,6233,249,59484,157Jun 05 04:03 PM
Moore Daniel JeffreyDirectorJun 03 '24Sale60.1156,6233,403,69427,534Jun 05 04:03 PM
Bolton StephaniePresident, Global EpilepsyMar 30 '24Option Exercise0.007,744013,205Apr 02 09:22 PM
Hebbelinck TruiChief Human Resources OfficerMar 30 '24Option Exercise0.0011,779019,320Apr 02 09:21 PM
Shvartsburg AlexCFOMar 30 '24Option Exercise0.0014,752024,133Apr 02 09:20 PM
Hutchinson Michael DamonChief Legal OfficerMar 30 '24Option Exercise0.001,47802,828Apr 02 09:18 PM
KOZY WILLIAM AChairman and CEOFeb 29 '24Option Exercise0.0014,512032,333Mar 04 05:22 PM
Saia Andrea LynnDirectorDec 31 '23Option Exercise0.001,468011,113Jan 03 04:14 PM
Hutchinson Michael DamonChief Legal OfficerDec 15 '23Option Exercise0.002,25402,254Dec 19 04:28 PM
Shvartsburg AlexCFODec 15 '23Option Exercise0.0061309,548Dec 19 04:16 PM
KOZY WILLIAM ADirectorOct 14 '23Option Exercise0.0010,311021,550Oct 17 08:01 PM
Story BrookeDirectorSep 15 '23Option Exercise0.001,72501,725Sep 19 05:08 PM
Hebbelinck TruiChief Human Resources OfficerSep 15 '23Option Exercise0.0044007,748Sep 19 04:58 PM